IFN-β therapy for MS is reported to work through several immunoregulatory mechanisms including increasing anti-inflammatory cytokines (22), down-regulation of pro-inflammatory TH1/TH17 cytokines (23, 24), reducing T cell activation and infiltration to the central nervous system (CNS) (25), and inducing neuroantigen-specific Treg cells (26). The gene discussed is IFNB1; the disease is myeloid sarcoma.